Q-omics provides the consensus-scored RPL35AP6 profile across patient tissues and cancer cell-line models. RPL35AP6 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RPL35AP6 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, RPL35AP6 RNA expression shows 13,545 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight BRCA, and LAML as cancer lineages where RPL35AP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35AP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35AP6 survival associations across molecular data types. RPL35AP6 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35AP6 RNA expression–survival associations across cancer types. High RPL35AP6 expression shows unfavorable associations in ACC, KICH, STAD and UVM, but favorable associations in BRCA and LAML. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for RPL35AP6 RNA expression.
This table summarizes RPL35AP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPL35AP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35AP6 shows lower tumor expression in KIRC and KIRP and higher tumor expression in BRCA, COAD, READ and PRAD. The BRCA box plot shows higher RPL35AP6 RNA expression in tumor versus normal tissue (log2 FC = +0.289, t-test p = .001).
This table shows molecular features associated with RPL35AP6 in patient tissues and cancer cell lines. In patient samples, RPL35AP6 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
